What's Ahead for Biosimilar Litigation?
What is ahead for biosimilar litigation? We highlight a recent interview Goodwin partners gave recently about their new guide to biosimilar litigation.
How Can Value-Based Care Embrace the Possibilities of Biosimilars?
In case you missed it: Jeffery Scott, MD, chief medical officer of Integra Connect, discussed what role biosimilars will play in a value-based system on a recent podcast episode of Not So Different.
Patients Say They Are Ready for Cost-Saving Biosimilar Insulin
Winnie Tiedemann, 73, of New Jersey lives with her son and his 5 children. Tiedemann was diagnosed with diabetes at age 25 and has been insulin-dependent for the past 20 or so years. Her out of pocket costs for insulin? Around $3600 a year.
2 Clarke Drive Cranbury, NJ 08512